文献速递肾癌与肾肿瘤

减瘤性肾切除与舒尼替尼暴露:SURTIME试验事后分析

Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
PubMed 文献 · BJU Int · 2021-11-24

SURTIME试验事后分析比较即刻与延迟减瘤性肾切除对舒尼替尼暴露的影响。延迟组97.7%接受舒尼替尼,即刻组80%;即刻组中位起始时间39.5天,延迟组4.5天。即刻减瘤性肾切除损害舒尼替尼给药、起始和持续时间,延迟组疾病控制更早更深。

要点

  • 延迟减瘤性肾切除组舒尼替尼接受率更高(97.7% vs 80%)。
  • 即刻组舒尼替尼中位起始时间显著延迟(39.5天 vs 4.5天)。
  • 延迟组舒尼替尼中位治疗持续时间更长(248天 vs 172.5天)。

核心结论

  • 与延迟减瘤性肾切除相比,即刻减瘤性肾切除损害舒尼替尼的给药、起始和持续时间。
  • 先全身治疗可早期、更深入控制疾病,并在计划减瘤性肾切除前识别进展,可能贡献观察到的总生存获益。

研究设计与样本

  • SURTIME试验事后分析,比较即刻与延迟减瘤性肾切除联合舒尼替尼的顺序。
  • 分析意向治疗人群中两组接受舒尼替尼的患者数、随机至起始时间、RECIST 1.1缓解率、药物暴露时长和剂量。

主要发现

  • 延迟组97.7%(95%CI 89.3-99.6%;n=48)接受舒尼替尼,即刻组80%(95%CI 66.9-88.7%;n=40)。
  • 即刻减瘤性肾切除后4周19.6%进展,中位起始舒尼替尼时间39.5天,延迟组4.5天。
  • 第16周时即刻组46.0%转移部位进展,延迟组32.7%。
  • 两组舒尼替尼剂量减少、增加和中断无统计学显著差异。
  • 接受舒尼替尼者中,即刻组中位总治疗持续时间172.5天,延迟组248天;延迟组靶病灶缩小更显著。

临床怎么用

  • 转移性肾癌拟行减瘤性肾切除者,可优先考虑全身治疗再手术以保障药物暴露。
  • 即刻减瘤性肾切除可能延迟舒尼替尼起始并缩短治疗持续时间。

局限性

  • 为SURTIME试验事后分析,样本量有限,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyse if exposure to sunitinib in the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial, which investigated opposite sequences of cytoreductive nephrectomy (CN) and systemic therapy, is associated with the overall survival (OS) benefit observed in the deferred CN arm. PATIENTS AND METHODS: A post hoc analysis of SURTIME trial data. Variables analysed included number of patients receiving sunitinib, time from randomisation to start sunitinib, overall response rate by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, and duration of drug exposure and dose in the intention-to-treat population of the immediate and deferred arm. Descriptive methods and 95% confidence-intervals (CI) were used. RESULTS: In the deferred arm, 97.7% (95% CI 89.3-99.6%; n = 48) received sunitinib vs 80% (95% CI 66.9-88.7%, n = 40) in the immediate arm. Following immediate CN, 19.6% progressed 4 weeks after CN and the median time to start sunitinib was 39.5 vs 4.5 days in the deferred arm. At week 16, 46.0% had progressed at metastatic sites in the immediate CN arm vs 32.7% in the deferred arm. Sunitinib dose reductions, escalations and interruptions were not statistically significantly different between arms. Among patients who received sunitinib in the immediate or deferred arm the median total sunitinib treatment duration was 172.5 vs 248 days. Reduction of target lesions was more profound in the deferred arm. CONCLUSIONS: In comparison to the deferred CN approach, immediate CN impairs administration, onset, and duration of sunitinib. Starting with systemic therapy leads to early and more profound disease control and identification of progression prior to planned CN, which may have contributed to the observed OS benefit.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Abu-Ghanem Y, van Thienen JV, Blank C, et al. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial. BJU Int. 2021. PMID: 34706141. doi:10.1111/bju.15625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。